Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH/DHHS, 6120 Executive Boulevard, EPS 3024, Rockville, MD 20852, USA.
Cancer Epidemiology Biomarkers & Prevention (Impact Factor: 4.32). 05/2004; 13(4):546-52.
Source: PubMed

ABSTRACT Vitamin D is a potential agent for the prevention of colorectal cancer possibly through mechanisms mediated by the vitamin D receptor (VDR). We investigated the association of circulating vitamin D metabolites and a genetic variant of the VDR gene with advanced colorectal adenoma, a precursor lesion of colorectal cancer.
Cases with advanced adenoma of the distal large bowel and gender- and ethnicity-matched controls with a negative sigmoidoscopy were randomly selected from participants in the Prostate, Lung, Colorectal and Ovarian Cancer Screening trial. Genotype analysis of the VDR TaqI polymorphism was completed on 763 cases and 774 controls. Serum levels of 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)(2)D] were measured in a subset of 394 cases and 397 controls.
Serum levels of 25(OH)D were inversely associated with advanced adenoma risk in women but not in men. Comparing those in the highest quintile with those in the lowest quintile, the risk for advanced adenoma decreased by 73% in women [odds ratio (OR) = 0.27, 95% confidence interval (95% CI) = 0.11-0.69; P for trend = 0.0002], while the risk did not decrease in men (OR = 1.10, 95% CI = 0.60-2.05; P for trend = 0.85). In women, 25(OH)D levels were significantly higher in current users of hormone replacement therapy (HRT) than in former or never HRT users. Neither serum 1,25(OH)(2)D nor VDR TaqI genotype was associated with advanced adenoma risk.
Higher serum 25(OH)D levels were associated with decreased adenoma risk. Serum 1,25(OH)(2)D and VDR TaqI genotype were not associated with adenoma risk.

  • [Show abstract] [Hide abstract]
    ABSTRACT: A number of studies have evaluated the role of gene-diet interaction in the etiology of colorectal cancer (CRC). Historically, these studies focused on established dietary risk factors and genes involved in their metabolism. However, results from these candidate gene studies were inconsistent, possibly due to multiple testing and publication bias. In recent years, genome-wide association studies have identified a number of CRC susceptibility loci, and subsequent meta-analyses have observed limited evidence that diet may modify the risk associated with these susceptibility loci. Statistical techniques have been recently developed to evaluate the presence of interaction across the entire genome; results from these genome-wide studies have demonstrated limited evidence of interaction and have failed to replicate results from candidate gene studies and those using established susceptibility loci. However, larger sample sizes are likely needed to elucidate modest or weak interaction in genome-wide studies of gene-diet interaction.
    12/2014; 4(1). DOI:10.1007/s13668-014-0114-2
  • [Show abstract] [Hide abstract]
    ABSTRACT: Inflammation, hormones, and energy-related factors have been associated with colorectal cancer (CRC) and it has been proposed that convergence and interactions of these factors importantly influence CRC risk. We have previously hypothesized that genetic variation in the CHIEF (Convergence of Hormones, Inflammation, and Energy-related Factors) Pathway would influence risk of CRC. In this paper, we utilize an adaptive rank truncation product (ARTP) statistical method to determine the overall pathway significance and then use that method to identify the key elements within the pathway associated with disease risk. Data from two population-based case-control studies of colon (n=1555 cases and 1956 controls) and rectal (n=754 cases and 959 controls) cancer were used. We use ARTP to estimate pathway and gene significance and polygenic scores based on ARTP findings to further estimate the risk associated with the pathway. Associations were further assessed based on tumor molecular phenotype. The CHIEF pathway was statistically significant for colon cancer (PARTP= 0.03) with the most significant interferons (PARTP =0.0253), JAK/STAT/SOCS (PARTP=0.0111), telomere (PARTP=0.0399), and TGFβ (PARTP=0.0043) being the most significant sub-pathways for colon cancer. For rectal cancer interleukins (PARTP=0.0235) and selenoproteins (PARTP= 0.0047) were statistically significant, although the pathway overall was of borderline significance (PARTP=0.06). Interleukins (PARTP=0.0456) and MAPK (PARTP=0.0392) sub-pathways were uniquely significant for CIMP+ colon tumors. Increasing number of at-risk alleles was significantly associated with both colon (OR =6.21 95% CI 4.72,8.16) and rectal (OR=7.82 95%CI 5.26,11.62) cancer.
    Carcinogenesis 10/2014; 36(1). DOI:10.1093/carcin/bgu213 · 5.27 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin D is hypothesized to prevent cancer development, and its potential anticarcinogenic effect against colorectal cancer has been explored in epidemiologic studies. Epidemiologic studies found that a low circulating level of 25-hydroxyvitamin D was associated with higher risk of colorectal cancer, whereas the association for vitamin D intake has not been as clear as for circulating vitamin D levels. A large intervention study on vitamin D supplementation and colorectal cancer did not show a protective benefit against colorectal cancer development, but several possible explanations remain open. Genetic polymorphisms in the pathway of vitamin D metabolism also have drawn attention, and single polymorphism studies and Genome Wide Association Studies (GWAS) have been conducted. Given a relatively high prevalence of vitamin D insufficiency among industrialized populations, further research on the optimal dose and duration of vitamin D supplementation, interaction with other nutrients or genes, and the appropriate timing of vitamin D interventions is warranted.
    03/2012; 2(1). DOI:10.1007/s13668-012-0037-8